VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
RCEL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
RCELAVITA Medical, Inc.
$3.97$99M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksRCELFinancials

AVITA Medical, Inc. (RCEL) Financials

30Y historyFree accessUpdated daily

Revenue growth remains erratic, fluctuating from a 66.7% surge in 2025Q1 to a 4.3% contraction by 2025Q4, while SG&A expenses continue to outpace top-line gains.

RCEL Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Jun'21Jun'20Jun'19Jun'18Jun'17Jun'16Jun'15Jun'14Jun'13Jun'12Jun'11Jun'10Jun'09Jun'08Jun'07Jun'06Jun'05Jun'04Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue72.35M71.61M64.25M50.14M34.42M33.02M29.23M14.26M5.47M1.26M1.18M1M985.65K2.68M2.81M3.35M3.34M2.3M2.37M1.2M790.99K883.39K720.25K389.08K194.32K000582.97K00
Revenue Growth %0.96%11.45%28.14%45.68%4.23%12.98%104.95%160.56%336.12%6.31%17.83%1.66%-63.27%-4.68%-16.03%0.5%45.24%-2.97%96.64%52.17%-10.46%22.65%85.12%100.23%----100%---
Cost of Goods Sold13.48M12.79M9.09M7.78M6.04M6.1M5.95M2.97M1.27M737.7K505.64K401.57K289.2K670.89K676.5K952.85K972.78K669.45K824.23K492.31K1.13M1.06M1.99M940.26K98.98K000000
COGS % of Revenue-17.87%14.15%15.52%17.55%18.48%20.35%20.84%23.22%58.77%42.83%40.08%29.34%25%24.03%28.42%29.16%29.15%34.82%40.9%142.69%120.02%276.9%241.66%50.94%------
Gross Profit58.86M58.82M55.16M42.36M28.38M26.92M23.28M11.29M4.2M517.47K675K600.44K696.45K2.01M2.14M2.4M2.36M1.63M1.54M711.35K-337.7K-176.85K-1.27M-551.18K95.34K000582.97K00
Gross Margin %81.36%82.13%85.85%84.48%82.45%81.52%79.65%79.16%76.78%41.23%57.17%59.92%70.66%75%75.97%71.58%70.84%70.85%65.18%59.1%-42.69%-20.02%-176.9%-141.66%49.06%---100%--
Gross Profit Growth %-6.63%30.2%49.27%5.42%15.63%106.23%168.62%712.22%-23.34%12.42%-13.79%-65.39%-5.9%-10.87%1.55%45.22%5.47%116.86%310.65%-90.95%86.12%-131.16%-678.15%----100%---
Operating Expenses98.38M100.75M111.75M85.02M55.88M52.04M49.82M53.97M29.73M19.15M13.35M11.95M9.26M8.83M10.77M10.66M7.89M5.23M5.91M5.75M8.75M9.62M6.54M4.87M169.38K670.01K76.87K235.7K371.78K97.16K138.81K
OpEx % of Revenue-140.69%173.93%169.55%162.36%157.57%170.44%378.38%543.13%1525.4%1130.34%1193.07%939.69%329.16%382.66%317.9%236.41%227.87%249.9%477.96%1106.56%1089.13%907.79%1250.47%87.17%---63.77%--
Selling, General & Admin78.19M79.91M91.39M65.63M45.24M37.21M37.06M48.73M27.65M21.21M13.9M10.93M5.68M7.09M8.92M8.64M7.57M4.55M5.24M5.37M7.28M7.54M5.37M3.05M848.25K480.4K569.49K235.7K371.78K97.16K138.81K
SG&A % of Revenue-111.59%142.24%130.88%131.44%112.68%126.78%341.66%505.08%1690.1%1177.51%1090.91%576.04%264.19%316.97%257.75%226.98%198.16%221.45%445.91%920.3%854.09%745.14%783.57%436.53%---63.77%--
Research & Development20.18M20.84M20.36M20.82M13.86M15.67M14.82M9.16M8M8.45M6.27M3.46M3.77M2.15M2.6M969.11K255.54K164.79K181.85K163.83K620.67K1.33M1.17M425.97K0000000
R&D % of Revenue-29.1%31.69%41.52%40.26%47.45%50.69%64.25%146.22%673.52%531.17%345.09%382.27%80.19%92.4%28.91%7.66%7.18%7.68%13.61%78.47%150.59%162.65%109.48%-------
Other Operating Expenses000-1.43M-3.21M-843K-2.06M-3.93M-5.92M00000000886.45K41.73K5.88K4.27M85.29K0240.35K-1.28M-24.61K-2.08M0000
Operating Income-39.51M-41.93M-56.59M-42.66M-27.5M-25.12M-26.54M-42.68M-25.53M-18.7M-12.67M-11.35M-8.74M-6.82M-8.63M-6.19M-4.38M-2.59M-4.06M-4.37M-4.54M-9.19M-7.81M-4.97M-1.62M-1.29M498.38K-235.7K1.51M-97.16K-138.81K
Operating Margin %-54.61%-58.56%-88.08%-85.07%-79.91%-76.06%-90.79%-299.23%-466.35%-1489.88%-1073.17%-1133.14%-887.04%-254.16%-306.69%-184.73%-131.31%-113%-171.55%-362.86%-574.37%-1040.57%-1084.69%-1278.53%-832.34%---258.39%--
Operating Income Growth %-25.9%-32.68%-55.08%-9.5%5.36%37.81%-67.19%-36.51%-47.59%-11.59%-29.86%-28.21%21.01%-39.41%-41.39%-68.78%36.09%7.04%3.86%50.58%-17.66%-57.05%-207.56%-25.28%-359.04%311.44%-115.65%1650.39%30.01%-9.69%
EBITDA-37.06M-39.59M-55.47M-42.02M-26.94M-24.45M-25.82M-42.21M-25.59M-18.6M-12.53M-11.27M-8.68M-6.76M-8.51M-5.62M-3.73M-2.08M-3.57M-4.15M-3.69M-8.45M-6.85M-4.27M-1.51M-1.1M575.24K359.65K582.97K-2.29M440.17K
EBITDA Margin %-51.22%-55.28%-86.33%-83.81%-78.26%-74.02%-88.34%-295.97%-467.5%-1481.48%-1061.34%-1124.79%-880.69%-251.79%-302.36%-167.75%-111.79%-90.46%-150.78%-344.42%-466.58%-956.13%-951.06%-1097.89%-774.79%---100%--
EBITDA Growth %25.54%28.63%-31.99%-56%-10.19%5.34%38.82%-64.96%-37.62%-48.4%-11.18%-29.84%-28.49%20.63%-51.36%-50.8%-79.5%41.79%13.91%-12.33%56.31%-23.3%-60.36%-183.73%-36.7%-291.46%59.95%-38.31%125.46%-620.17%134.22%
D&A (Non-Cash Add-back)2.45M2.35M1.13M632K568K673K715K465K-63K105.45K139.7K83.72K62.62K63.71K121.92K569.23K650.88K517.57K491.49K221.97K852.62K745.94K962.51K702.81K111.83K189.6K76.87K595.35K-923.38K-2.19M578.99K
EBIT-39.78M-41.93M-56.43M-34.17M-26.61M-25.08M-26.52M-41.99M-25.2M-18.7M-12.67M-11.35M-8.74M-6.82M-8.63M-6.19M0-2.59M-4.06M-4.37M-4.54M-9.19M-7.44M-4.97M00498.38K-235.7K1.51M-97.16K-138.81K
Net Interest Income-5.51M-5M-5.36M-1.14M23.5K-29K-33K47.82K-27K28.37K110.95K110.34K45.42K160.33K412.26K509.64K112.09K87.05K191.61K615.01K-8.01M515.64K363.22K191.7K142.88K126.13K-4.77M-569.55K-2.07M-2.19M-258.33K
Interest Income000023.5K0047.82K028.37K110.95K110.34K45.42K160.33K412.26K509.71K124.99K124.7K270.11K668.21K543.41K520.5K369.88K201.65K145.15K126.13K195.94K6.81K6104.2K0
Interest Expense5.51M5M5.36M1.14M16K29K33K027K0000006912.9K37.65K78.5K53.2K8.55M4.86K6.66K9.95K2.27K44.97M576.36K2.07M2.19M258.33K
Other Income/Expense-5.84M-6.64M-5.2M7.34M876K18K-5K653K305K43.24K110.95K110.34K222.97K160.33K412.26K-1.57M3.23M-1.82M41.73K-7.58M-4.55M85.29K390.66K240.35K-1.58M-735.53K-1.16M-567.08K-956K-1.56M1.52M
Pretax Income-45.35M-48.58M-61.79M-35.31M-26.63M-25.1M-26.55M-42.03M-25.22M-18.66M-12.56M-11.24M-8.52M-6.66M-8.22M-7.76M-2.18M-5.34M-4.14M-12M-13.09M-9.2M-7.42M-4.98M-1.51M-1.29M-1.63M-812.06K-563.08K-2.29M184.42K
Pretax Margin %-62.68%-67.83%-96.17%-70.43%-77.36%-76%-90.81%-294.65%-460.78%-1486.44%-1063.77%-1122.13%-864.42%-248.18%-292.04%-231.47%-65.24%-232.33%-174.86%-997.23%-1655.44%-1041.12%-1030.45%-1281.09%-775.96%----96.59%--
Income Tax-9K11K54K66K36K42K38K4K-121K1.45M1.05M971.88K653.67K1.51M128.05K87.76K-90.09K-330.41K78.5K-342.23K-316.55K-311.92K-301.11K-7.13M-2.69M-2.53M-2.94M576.36K-923.38K2.19M-581.57K
Effective Tax Rate %0.02%-0.02%-0.09%-0.19%-0.14%-0.17%-0.14%-0.01%0.48%-7.78%-8.35%-8.64%-7.67%-22.7%-1.56%-1.13%4.14%6.19%-1.9%2.85%2.42%3.39%4.06%143.03%178.3%195.91%179.53%-70.97%163.99%-95.76%-315.35%
Net Income-45.34M-48.59M-61.84M-35.38M-26.66M-25.14M-26.58M-42.03M-25.1M-17.21M-11.51M-10.27M-7.87M-5.15M-8.09M-7.59M-2.09M-5.01M-4.14M-11.66M-12.78M-8.89M-7.12M-4.98M-1.54M-1.12M-1.54M-812.06K-562.85K-2.29M184.42K
Net Margin %-62.67%-67.85%-96.26%-70.56%-77.47%-76.13%-90.94%-294.68%-458.57%-1370.83%-974.99%-1025.14%-798.1%-191.84%-287.49%-226.42%-62.54%-217.95%-174.86%-968.8%-1615.42%-1005.81%-988.65%-1281.09%-794.76%----96.55%--
Net Income Growth %20.52%21.44%-74.8%-32.69%-6.06%5.42%36.75%-67.44%-45.89%-49.48%-12.06%-30.58%-52.82%36.4%-6.62%-263.84%58.32%-20.93%64.51%8.74%-43.81%-24.78%-42.86%-222.75%-37.68%26.98%-89.17%-44.28%75.42%-1341.54%114.35%
Net Income (Continuing)-45.34M-48.59M-61.84M-35.38M-26.66M-25.14M-26.58M-42.03M-25.1M---------5.01M--11.66M-12.78M--7.12M--------
Discontinued Operations0000000000000000000000000000000
Minority Interest0000000000000000000000000-15.51K169.88K0000
EPS (Diluted)-0.15-1.74-2.39-1.40-1.07-1.03-1.17-3.00-1.12-1.85-1.72-2.06-2.23-1.58-2.69-3.19-1.53-3.93-3.75-16.51-3.24-3.43-0.18-3.14-1.92-0.56-0.80-1.32-2.25-48.58-0.74
EPS Growth %28.31%27.2%-70.71%-30.84%-3.88%11.97%61%-167.86%39.46%-7.56%16.5%7.62%-41.14%41.26%15.67%-108.5%61.07%-4.8%77.29%-409.57%5.54%-1805.56%94.27%-63.54%-242.86%30%39.39%41.33%95.37%-6464.86%97.29%
EPS (Basic)--1.74-2.39-1.40-1.07-1.03-1.17-3.00-1.12-1.84-1.72-2.06-2.23-1.58-2.69-3.19-1.13-3.93-3.75-16.51-3.24-3.43-0.18-3.14-1.92-0.56-0.80-1.32-2.25-48.58-0.74
Diluted Shares Outstanding305.41M27.86M25.88M25.33M25M24.36M20.29M20.29M22.33M9.33M6.7M4.99M3.53M3.25M3.01M2.38M1.84M1.27M1.1M706.45K3.94M2.59M38.53M1.59M806.03K2M1.93M614.53K249.7K47.13K47.13K
Basic Shares Outstanding305.41M27.86M25.88M25.33M25M24.36M20.29M20.29M22.33M9.3M6.69M4.99M3.53M3.25M3.01M2.38M1.84M1.27M1.1M706.45K3.94M2.59M38.53M1.59M806.03K2M1.93M614.53K249.7K47.13K47.13K
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Insufficient liquidity for operations

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Lacks Consistent Momentum

According to the latest quarterly data, RCEL's revenue growth has become increasingly erratic, fluctuating from a 66.7% surge in 2025Q1 to a 4.3% contraction by 2025Q4, suggesting that the company's transition into new trauma and vitiligo indications has yet to yield a predictable, scalable revenue trajectory.

The volatility in top-line performance indicates that the company is struggling to convert its expanded clinical indications into consistent procedural volume. Investors should monitor whether the recent 4.0% growth in 2026Q1 represents a stabilization or a continued deceleration as the initial excitement of new market entry fades.

High Gross Margins Mask Operational Inefficiency

As reported in financial statements, RCEL maintains a robust gross margin profile averaging above 80%, yet this structural strength is currently overshadowed by an operating margin that remains deeply negative, reflecting the heavy burden of commercializing specialized regenerative medicine products in a competitive hospital environment.

While the 82.13% gross margin confirms the high value-add of the RECELL kit, the inability to translate this into positive operating income suggests that the current sales model is prohibitively expensive. The company appears to be trapped in a high-touch clinical support cycle that prevents the realization of meaningful operating leverage.

SG&A Expenses Outpace Revenue Gains

Based on reported figures, RCEL's SG&A spending has remained stubbornly high, often exceeding total revenue in recent quarters, which indicates that the company's aggressive investment in its field force has not yet achieved the necessary efficiency to drive the business toward a sustainable path to profitability.

The persistent level of SG&A spending suggests that management is prioritizing market share acquisition over expense discipline. This strategy warrants further investigation, as the lack of a clear downward trend in operating expenses relative to revenue may indicate that the current commercial footprint is structurally oversized for the current volume.

Liquidity Constraints Threaten Operational Continuity

Data from recent filings reveals a precarious cash position of $10.2M against a TTM operating loss of nearly $48M, which suggests that the company faces a significant risk of dilutive financing or liquidity shortfalls that could impair its ability to execute on its long-term growth strategy.

The current cash burn rate appears unsustainable without a near-term capital injection, which would likely be dilutive to existing shareholders. Investors should be wary of the company's reliance on external funding to bridge the gap between its current operating losses and the theoretical future profitability of its new indications.

RCEL — Frequently Asked Questions

Quick answers to the most common questions about buying RCEL stock.

What was AVITA Medical, Inc.'s (RCEL) revenue in 2025?

For fiscal year 2025, AVITA Medical, Inc. (RCEL) reported total revenue of $71.6M.

Is AVITA Medical, Inc. (RCEL) profitable?

AVITA Medical, Inc. (RCEL) reported a net loss of $48.6M for the fiscal year ending 2025.

What is AVITA Medical, Inc.'s operating profit margin?

AVITA Medical, Inc. (RCEL) reported an operating income of $-41.9M, resulting in an operating profit margin of -58.6%. This margin reflects the operational efficiency of the business before interest and taxes.

What is AVITA Medical, Inc.'s gross profit and gross margin?

AVITA Medical, Inc. (RCEL) generated $58.8M in gross profit for the year, representing a gross profit margin of 82.1%. This demonstrates the company's core pricing power and production efficiency.